Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From CryoLife, Inc.
The disruptive medtech M&A of recent years was not matched in the past year for volume, but there were isolated outbreaks of major activity, as shown in our company rankings.
Private Company Edition: VC deals are surging this year for cell and gene therapy firms, according to ARM’s third quarter report. Also, Vivo Capital and the CF Foundation plan to invest nearly $2bn in health care and life science opportunities, and Akeso completes $150m series D.
Former Medivation CEO David Hung launched stealthy oncology start-up Nuvation with $275m in series A venture capital, while Tenaya's series B brought in $92m for small molecules as well as cell and gene therapies to treat cardiovascular diseases.
Derived from Strategic Transactions, Informa's premium source for tracking life-sciences deals, the bimonthly Pacts In Medtech feature highlights notable technology alliances, research and development partnerships and commercial collaborations. This edition covers industry pacts that were signed in September and October 2019.
- Implantable Devices
- Other Names / Subsidiaries
- Cardiogenesis Corporation
- CryoLife Asia Pacific, Pte. Ltd.
- CryoLife Europa Ltd
- CryoLife France, SAS
- JOTEC AG
- JOTEC Cardiovascular SL.
- JOTEC Polska Sp. z o.o.
- JOTEC s.r.l.
- On-X Life Technologies Holdings, Inc.